Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients

ASH 2019: Results of a study investigating Venetoclax combined with Ibrutinib and Obinutuzumab for first line treatment of MCL.